Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-106 in NTRK fusion-positive solid tumors
NCT04617054Phase 2Terminated
- Sponsor
- Nuvation Bio
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taletrectinib in solid tumor, sponsored by Nuvation Bio. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2021; status: terminated.
02
Drugs
taletrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04617054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617054.